|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical impact of circulating oncogenic MiRNA-221 and MiRNA-222 in glioblastoma multiform.
|
31422498 |
2019 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, the functions of miR-221/222 on glioblastoma cell angiogenesis were measured in vivo with microvessel density assayed. miR-221 and miR-222 were expressed at a high level and SOCS3 was at a low level in glioblastoma.
|
31106423 |
2019 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR 125b-5p, miR 181d-3p, and miR 221-3p are useful in predicting poor prognosis in patients with MGMT-unmethylated glioblastomas.
|
29538610 |
2018 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aims at validating microRNA-221 (miR-221) as a biomarker for glioblastoma, and understanding how miR-221 regulates glioblastoma progression.
|
27837435 |
2017 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knocking down of miR-221/222 significantly increased radiosensitivity of glioblastoma cells.
|
24295494 |
2014 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-221 targeting PI3-K/Akt signaling axis induces cell proliferation and BCNU resistance in human glioblastoma.
|
24780067 |
2014 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ.
|
21743492 |
2012 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We transfected miR-221/222 antisense oligonucleotides (AS-miR-221/222) into U251 human glioblastoma cells using a lipofectamine method.
|
22294051 |
2012 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we designed adenovirally-expressed shRNAs that functionally co-repressed the expression of miR-221 and miR-222, which are related to glioblastoma, to overcome the low efficiency of gene therapy.
|
21109963 |
2011 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this work, we report that the ectopic modulation of NF-kB modifies miR-221/222 expression in prostate carcinoma and glioblastoma cell lines, where we had previously shown their oncogenic activity.
|
21245048 |
2011 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The up-regulation of miR-221 has been reported in carcinomas of the pancreas, breast, and papillary thyroid, as well as in glioblastoma and chronic lymphocytic leukaemia.
|
21378318 |
2011 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma.
|
20813046 |
2010 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MiR-221 (p=0.016), miR-222 (p=0.038), miR-181b (p=0.036), miR-181c (p=0.043) and miR-128a (p=0.001) were significantly down-regulated in glioblastomas.
|
20353279 |
2010 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Global changes of mRNA expression reveals an increased activity of the interferon-induced signal transducer and activator of transcription (STAT) pathway by repression of miR-221/222 in glioblastoma U251 cells.
|
20428775 |
2010 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antagonism of either microRNA 221 or 222 in glioblastoma cells also caused an increase in p27(Kip1) levels and enhanced expression of the luciferase reporter gene fused to the p27(Kip1) 3'UTR.
|
17721077 |
2007 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The most interesting results came from miR-221, strongly up-regulated in glioblastoma and from a set of brain-enriched miRNAs, miR-128, miR-181a, miR-181b, and miR-181c, which are down-regulated in glioblastoma.
|
16039986 |
2005 |